| Literature DB >> 28723103 |
Louis Jeanne-Julien1, Guillaume Masson1, Eloi Astier1, Grégory Genta-Jouve1, Vincent Servajean2, Jean-Marie Beau2,3, Stéphanie Norsikian2, Emmanuel Roulland1.
Abstract
Tiacumicin B is an antibiotic endowed with the remarkable ability to interact with a new biological target, giving it an inestimable potential in the context of the ever-growing and worrisome appearance of resistances of bacteria and mycobacteria to antibiotics. The synthesis of an aglycone of tiacumicin B ready for glycosylation is reported. The key steps of this approach are a [2,3]-Wittig rearrangement, a Pd/Cu-catalyzed allene-alkyne cross-coupling, a E-selective cross-metathesis, and a final ring-size selective macrolactonization.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28723103 DOI: 10.1021/acs.orglett.7b01744
Source DB: PubMed Journal: Org Lett ISSN: 1523-7052 Impact factor: 6.005